» Articles » PMID: 32886826

Changing Patterns in the Epidemiology of β-thalassemia

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2020 Sep 4
PMID 32886826
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

β-thalassemia major is an inherited hemoglobinopathy that requires lifelong red blood cell transfusions and iron chelation therapy to prevent complications due to iron overload. Traditionally, β-thalassemia has been more common in certain regions of the world such as the Mediterranean, Middle East, and Southeast Asia. However, the prevalence of β-thalassemia is increasing in other regions, including Northern Europe and North America, primarily due to migration. This review summarizes the available data on the changing incidence and prevalence of β-thalassemia as well as factors influencing disease frequency. The data suggest that the epidemiology of β-thalassemia is changing: Migration has increased the prevalence of the disease in regions traditionally believed to have a low prevalence, while, at the same time, prevention and screening programs in endemic regions have reduced the number of affected individuals. Various approaches to prevention and screening have been used. Region-specific prevention and treatment programs, customized to align with local healthcare resources and cultural values, have been effective in identifying patients and carriers and providing information and care. Significant challenges remain in universally implementing these programs.

Citing Articles

TIF Guidelines for the Management of Transfusion-Dependent β-Thalassemia.

Musallam K, Cappellini M, Porter J, Farmakis D, Eleftheriou A, Angastiniotis M Hemasphere. 2025; 9(3):e70095.

PMID: 40045934 PMC: 11880825. DOI: 10.1002/hem3.70095.


Experiences of family caregivers of children living with thalassaemia-major in Karachi: a phenomenological study.

Baqar M, Ahmed J, Asim M, Pradhan N, Altaf S BMJ Public Health. 2025; 2(2):e001359.

PMID: 40018539 PMC: 11816845. DOI: 10.1136/bmjph-2024-001359.


Combined heterozygosity for hemoglobin Paksé, α-thalassemia and for hemoglobin E, β- thalassemia ̵ first appearance in Europe.

Schnedl W, Leixner G, Voill-Glaninger A, Michaelis S, Enko D, Mangge H Ann Hematol. 2025; .

PMID: 40016398 DOI: 10.1007/s00277-025-06286-1.


Are Mitochondria a Potential Target for Treating β-Thalassemia?.

Pierro E, Stefano V, Migone De Amicis M, Graziadei G J Clin Med. 2025; 14(4).

PMID: 40004626 PMC: 11856739. DOI: 10.3390/jcm14041095.


Iron Overload-Related Oxidative Stress Leads to Hyperphosphorylation and Altered Anion Exchanger 1 (Band 3) Function in Erythrocytes from Subjects with β-Thalassemia Minor.

Spinelli S, Straface E, Gambardella L, Caruso D, Dossena S, Marino A Int J Mol Sci. 2025; 26(4).

PMID: 40004059 PMC: 11855117. DOI: 10.3390/ijms26041593.


References
1.
Michlitsch J, Azimi M, Hoppe C, Walters M, Lubin B, Lorey F . Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer. 2008; 52(4):486-90. PMC: 4755934. DOI: 10.1002/pbc.21883. View

2.
Savongsy O, Fucharoen S, Fucharoen G, Sanchaisuriya K, Sae-Ung N . Thalassemia and hemoglobinopathies in pregnant Lao women: carrier screening, prevalence and molecular basis. Ann Hematol. 2008; 87(8):647-54. DOI: 10.1007/s00277-008-0490-z. View

3.
Geitona M, Karagianni V, Kattamis A, Voskaridou E, Drosou M, Vini D . The Economic Burden of Treating Thalassemia In Greece. Value Health. 2016; 17(7):A526. DOI: 10.1016/j.jval.2014.08.1661. View

4.
Ladis V, Karagiorga-Lagana M, Tsatra I, Chouliaras G . Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation. Eur J Haematol. 2013; 90(4):313-22. DOI: 10.1111/ejh.12076. View

5.
Hussein G, Fawzy M, Serafi T, Ismail E, Metwally D, Saber M . Rapid detection of beta-Thalassemia alleles in Egypt using naturally or amplified created restriction sites and direct sequencing: a step in disease control. Hemoglobin. 2007; 31(1):49-62. DOI: 10.1080/03630260601057088. View